Faron Pharmaceuticals (FARN) Corporate presentation summary

Disease focus and mechanism

• HR MDS is a lethal blood cancer with ~40,000 new cases annually across the US and EU5; no approved standard second-line therapy.

• CLEVER-1 is expressed by leukemic myeloid cells and immunosuppressive macrophages; high expression in cancer is associated with poor prognosis and treatment resistance.

• Bexmarilimab targets CLEVER-1 to reprogram monocytes and activate antitumor immunity; it may also reduce blast energy production, sensitizing cancer cells to existing therapies.

• MATINS treated 216 patients across 10 cancer types; bexmarilimab was well tolerated, with an FDA-supported RP2D of 1 mg/kg every 3 weeks and reported tumor-microenvironment modulation.

BEXMAB clinical findings

• Phase 1/2 enrolled treatment-naïve HR MDS patients (n=21) and HMA-failed relapsed/refractory patients (n=34), including high- and very-high-risk disease.

• Frontline patients had a 45% CR rate and 16-month CR duration; 67% of patients with CR were MRD-negative, and 57% of transfusion-dependent patients became transfusion-independent.

• In relapsed/refractory MDS, ORR was 21/33 (64%); responses included 2 CRs (6%) and 14 marrow CRs (42%).

• Relapsed/refractory median OS was 14.5 months overall; by dose, 3 mg/kg had 14.7 months versus 9.4 months at 6 mg/kg.

• At 3 mg/kg versus 6 mg/kg, grade ≥3 bexmarilimab-related AEs were 24% versus 42%, and TEAEs leading to drug withdrawal were 12% versus 27%.

Development plans and catalysts

• Phase IIb BEXMAB-2 FPI is anticipated in H2 2026, with readout expected in 2027; Phase III FPI is planned for 2028.

• Planned Phase II includes ~90 patients across three arms; the combined Phase II/III plan is ~350 patients, with ~256 Phase III patients needed if CR is the sole endpoint.

• Additional H2 2026 FPI plans include BLAZE (bexmarilimab plus anti-PD-1), BEXAR (sarcoma), BEAM (AML) and an oral relapsed/refractory MDS study.

• Cash runway extends to YE 2027, covering the Phase IIb HR MDS readout and multiple Phase 1/2 solid-tumor readouts.